2003/8/159 |
BOCS (Formely FBCS) |
31/12/2020 |
2001-11-162 |
TEAM |
01/01/2019 |
1903782 |
A phase 2 study of LAG525 with PDR001 and carboplatin in advanced TNBC |
07/02/2021 |
1902773 |
DANTE (Duration of Anti-PD1 therapy for melanoma) |
28/02/2023 |
1902765 |
Ribociclib Non-Interventional Study |
15/08/2022 |
1901755 |
Ferring 000108 PRONOUNCE |
15/04/2022 |
1901749 |
CALLS – CML and ALL Low Level Mutation Study |
31/12/2018 |
1901747 |
MUK nine b: OPTIMUM |
31/12/2021 |
1901746 |
MUK nine a: screening study |
15/01/2024 |
1812732 |
Daiichi Sankyo DS8201-A-U201 (DS-8201a) |
30/04/2019 |
1812731 |
B-AHEAD3: Breast Activity and Healthy Eating After Diagnosis 3 |
28/02/2020 |
1810700 |
PLATO – PersonaLising Anal cancer radioTherapy dOse |
31/01/2022 |
1810695 |
OPINION, Olaparib Maintenance Monotherapy Ovarian Cancer. |
30/09/2020 |
1805632 |
National Lung Matrix: Multi-Drug Phase II trial in NSC Lung Cancer |
01/10/2021 |
1805629 |
ROVA-T Maintenance in SCLC (MERU) |
30/04/2020 |
1805626 |
LCH-IV |
01/12/2025 |
1804571 |
Open Label Study of Relugolix in Men with Advanced Prostate Cancer |
30/11/2019 |
1803566 |
CTC-STOP |
31/01/2021 |
1802579 |
PRAN-16-52 Pracinostat in combination with Azacitidine in Adult AML |
30/12/2019 |
1802571 |
CR UK Stratified Medicine Pilot study |
31/12/2020 |
1712545 |
CITADEL-202: Safety and Efficacy of INCB050465 in B-Cell Lymphoma |
01/06/2020 |
1712541 |
Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study |
14/03/2019 |
1712540 |
CHRONOS-4 |
25/02/2025 |
1710507 |
Niraparib in men with mCRPC and DNA repair anomalies |
30/06/2020 |
1708490 |
PRIMETIME |
24/01/2021 |
1708470 |
plasmaMATCH |
31/05/2019 |
1707467 |
CompLEEment-1 |
09/11/2020 |
1706435 |
Myeloma XII (ACCoRd trial) Version 1.0 |
31/01/2026 |
1706433 |
MUK8 |
31/12/2018 |
1704408 |
DETECT I |
01/02/2019 |
1704403 |
TREATT: Trial to EvaluAte Tranexamic acid therapy in Thrombocytopenia |
31/08/2019 |
1703398 |
CANC – 4658 |
18/09/2021 |
1703394 |
IMRiS |
30/09/2020 |
1703390 |
CONCEPT: A Phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of Her2 negative metastatic breast cancer (mBC) |
31/12/2020 |
1702383 |
CANC 5507 |
14/06/2019 |
1702380 |
CANC 5081 |
30/08/2019 |
1702374 |
Prepare-ABC |
01/05/2020 |
1612350 |
INCA |
30/04/2021 |
1610318 |
AML19 |
09/11/2031 |
1610314 |
HART |
31/01/2023 |
1608296 |
Hartmann’s procedure versus intersphincteric APE: a prospective study |
30/06/2019 |
1607275 |
DARS |
01/06/2020 |
1605234 |
EMBARK:MDV3100-13 Phase3, Enzalutamide, nonmetastatic Prostate Cancer |
30/11/2020 |
1604237 |
SelPac |
31/12/2018 |
1604233 |
CANC – 4039 – Pharmacokinetics of Ramucirumab in Second Line Gastric Adenocarcinoma (JVDB) |
01/05/2022 |
1603225 |
ACELARATE |
31/12/2020 |
1603223 |
CANC – 4556 |
31/03/2019 |
1602212 |
CompARE Trial |
01/11/2020 |
1601206 |
MelMarT |
31/12/2026 |
1601198 |
Add-Aspirin Trial |
15/08/2030 |
1512190 |
NCRN – 3312 – MPDL3280A vs Chemotherapy in Urothelial Bladder Cancer |
15/06/2021 |
1508136 |
MCL Biobank Observational Study |
30/10/2019 |
1507112 |
STAR Standard vs Modified Drug Therapy in Renal Cancer |
20/02/2019 |
1503071 |
FLAIR |
30/01/2020 |
1502056 |
The Molecular Investigation of Unexplained Anaemias |
30/11/2023 |
1411013 |
FOCUS 4 |
01/04/2020 |
1408976 |
DESTINY |
20/09/2019 |
1407965 |
De-ESCALaTE HPV |
01/01/2022 |
1406946 |
NCRN – 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC |
23/01/2024 |
1312865 |
NCRN487 ECHELON-1: A+AVD vs ABVD in first line advanced Hodgkin Lymphoma |
11/04/2020 |
1311856 |
RAPPER |
31/03/2022 |
1309829 |
BRF115532 |
01/01/2030 |
1305779 |
IoN |
01/02/2019 |
1301726 |
UKALL 2011 |
30/04/2019 |
1210712 |
INTERLACE |
01/12/2019 |
1210711 |
ESPAC-4 |
31/12/2018 |
1207674 |
SEARCH |
30/09/2019 |
1206664 |
FAST-Forward |
31/08/2028 |
1204623 |
Aristotle |
29/06/2019 |
1008419 |
Expression of tumour specific proteins during metastasis |
31/08/2020 |
1002346 |
IMPACT |
31/12/2018 |
907288 |
RADICALS (MRC PR10) |
01/05/2020 |
902246 |
MDSBio |
24/06/2021 |
810202 |
AVAST-M |
01/03/2022 |
809194 |
ALTTO – Adjuvant Lapatinib and/or Trastuzumab |
01/02/2021 |